THC Therapeutics, Inc. has filed its first 10-K annual report since undergoing corporate transformation, marking a significant step toward regaining full current reporting status. The company believes its current trading price on the OTC Expert Market does not reflect the underlying value of its operating businesses and assets, attributing this disconnect primarily to its reporting status. As the company completes its filings and returns to a fully current reporting position, it expects improved visibility, expanded market access, and more efficient price discovery.
The company has accelerated its growth strategy through transformative acquisitions of operating companies in cannabis cultivation, distribution, manufacturing, and ancillary support businesses. These acquisitions include successful regional cannabis brands and real estate holdings, laying the foundation for THC Therapeutics' expansion into the national cannabis scene. CEO Scott Cox stated that the recent acquisition has created a strong foundation and offers a model for growth moving forward, with the company remaining focused on growing its portfolio, revenues, and overall profitability.
To date, THC Therapeutics has acquired six companies operating under The Headquarters Group, Inc., a Medford, Oregon-based holding company. The portfolio includes Jefferson Soul, a well-established cultivation and extraction company located in Mt. Shasta, California with two indoor cultivation facilities and established regional brands. Jefferson Soul operates in The Emerald Triangle, a mountainous rural area encompassing parts of Northern California and Southern Oregon known for its cannabis heritage. The company's mission is to keep a culture of independence alive, as detailed on their website at https://www.jefferson-soul.com.
The portfolio also includes Kalix, a commercial-scale specialty nutrient and fertilizer brand with nationwide and international sales that was created specifically for cannabis cultivation. According to their website at https://www.kalixcpn.com, Kalix was born out of necessity at a time when there were very few specialty cannabis fertilizers available. NPK Industries, another portfolio company, serves hobby and home gardeners with nutrients and fertilizers sold nationwide and internationally through their website at https://www.npk-industries.com.
Harvest Food for Life represents the company's international nutrient and fertilizer operations with unique opportunities in West Africa, including potential work with the Niger Government to help alleviate food insecurity risks. Their operations are detailed at https://www.harvestfoodforlife.com. The real estate component of the portfolio includes Shasta Properties Management, which owns two separate specialty buildings fitted for commercial indoor cannabis cultivation, and Blue Sky Investments, which owns warehousing and distribution space for bulk nutrients and fertilizers along with a 5,000 square-foot retail showroom.
This diversified portfolio across different sectors of the cannabis industry offers the company unique advantages, positioning it to capitalize on multiple market opportunities. Currently operating in two states, THC Therapeutics continues to evaluate a healthy pipeline of new deal-flow and potential acquisitions that complement its existing portfolio. The company has initiated strategic divestitures of non-core, lower-performing assets to optimize its portfolio mix while retaining specialized investment banking services and engaging New York City-based securities counsel.
To enhance communication with the investment community, THC Therapeutics plans to hire an experienced investor relations firm to help effectively convey its value proposition, growth strategy, and operational achievements to current and potential shareholders. The company's proactive approach to portfolio management allows it to optimize asset mix and focus on opportunities with the highest potential for growth and returns. By capitalizing on both the growth in the national cannabis market and the growing pains of a new industry, THC Therapeutics seeks to enhance the overall quality and performance of its portfolio while creating sustainable value for shareholders.
